NCT05221827 is a clinical trial of C2i Test in Muscle-Invasive Bladder Carcinoma, sponsored by C2i Genomics.

Who is sponsoring NCT05221827?

NCT05221827 is sponsored by C2i Genomics.

What drugs are being tested in NCT05221827?

Interventions in NCT05221827: C2i Test.

What condition does NCT05221827 study?

NCT05221827 studies Muscle-Invasive Bladder Carcinoma.

Is NCT05221827 still recruiting?

NCT05221827 is currently terminated. Last updated 27 February 2023.

Last reviewed 2023-02-27 · How we verify

NCT05221827

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Performance Evaluation of the C2i-Test

Terminated Last updated 27 February 2023

What this trial tests

trial testing C2i Test in Muscle-Invasive Bladder Carcinoma in 3 participants. Terminated before completion.

Timeline

24 February 2022

Primary endpoint
27 July 2022

27 July 2022

Quick facts

Lead sponsor	C2i Genomics
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	3
Start date	24 February 2022
Primary completion	27 July 2022
Estimated completion	27 July 2022
Sites	1 location across United States

Drugs / interventions tested

C2i Test

Conditions studied

Muscle-Invasive Bladder Carcinoma — all drugs for Muscle-Invasive Bladder Carcinoma →

Sponsor

C2i Genomics — full company profile →

Who can join

Adults 22 to 100, any sex, with Muscle-Invasive Bladder Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA. The C2i-Test is a single site assay performed in the C2i Genomics' CLIA-certified laboratory. This is a prospective non-interventional study to collect definitive evidence of the safety and effectiveness of C2i-Test for the intended use, in a statistically justified number of subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Muscle-Invasive Bladder Carcinoma

Currently open trials in the same condition.

NCT07339761 — Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study · NA · recruiting
NCT07234968 — Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy · NA · recruiting
NCT06537154 — NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment · Phase 2, PHASE3 · recruiting
NCT06470282 — Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer · Phase 1, PHASE2 · recruiting
NCT06529822 — Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05221827 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by C2i Genomics
Last refreshed: 27 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05221827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing